Drugs / GB263T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05332574 | May 2022 → Jun 2024 | non-small cell lung carcinoma | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB263T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05332574 ↗ |
| Route | Intravenous | “Participants will receive IV infusions of GB263T” NCT05332574 ↗ |
| Target | EGFR | “Trispecific EGFR/cMET/cMET Antibody” NCT05332574 ↗ |
| Target | MET | “Trispecific EGFR/cMET/cMET Antibody” NCT05332574 ↗ |